Vertigoheel induced psychosis: A patient case report.

The Mental Health Clinician Pub Date : 2021-01-08 eCollection Date: 2021-01-01 DOI:10.9740/mhc.2021.01.031
Megan O'Connell, Elizabeth Hunt, Amy VandenBerg
{"title":"Vertigoheel induced psychosis: A patient case report.","authors":"Megan O'Connell,&nbsp;Elizabeth Hunt,&nbsp;Amy VandenBerg","doi":"10.9740/mhc.2021.01.031","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To describe a case of a patient who developed psychosis after ingestion of Vertigoheel for treatment of dizziness.</p><p><strong>Case summary: </strong>A 28-year-old male with no psychiatric history presented with 5 days of worsening depression and psychosis. He denied current use of prescription medications, alcohol, or illicit substances. Approximately 2 weeks prior, while visiting family in Germany, he developed dizziness. A provider in Germany prescribed Vertigoheel, 1 tablet to be taken every hour until symptom improvement. This did not improve his dizziness but did cause him to feel as if he were \"in a dream.\" He stopped taking the medication after 2 days but continued to feel amotivated with decreased appetite and insomnia. Several days later, he developed ego-dystonic auditory hallucinations. He returned to the United States; was admitted to an inpatient psychiatric unit for 4 days; and given olanzapine 5 mg at bedtime, lorazepam 1 mg every evening, and melatonin 6 mg every evening. He experienced gradual improvement in symptoms and was discharged with olanzapine 5 mg daily and outpatient follow-up.</p><p><strong>Discussion: </strong>Vertigoheel is a homeopathic preparation containing ambra grisea, <i>Cocculus indicus</i>, <i>Conium maculatum</i>, and petroleum. Psychosis was not reported in any of the randomized controlled trials evaluating the use of Vertigoheel for treatment of vertigo. A literature search revealed no published reports of psychosis as a result of administration of any components of Vertigoheel.</p><p><strong>Conclusion: </strong>A possible causal relationship was observed between the homeopathic supplement Vertigoheel and an acute episode of psychosis in a young male patient with no comorbidities.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"11 1","pages":"31-34"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/29/i2168-9709-11-1-31.PMC7800325.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Mental Health Clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/mhc.2021.01.031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To describe a case of a patient who developed psychosis after ingestion of Vertigoheel for treatment of dizziness.

Case summary: A 28-year-old male with no psychiatric history presented with 5 days of worsening depression and psychosis. He denied current use of prescription medications, alcohol, or illicit substances. Approximately 2 weeks prior, while visiting family in Germany, he developed dizziness. A provider in Germany prescribed Vertigoheel, 1 tablet to be taken every hour until symptom improvement. This did not improve his dizziness but did cause him to feel as if he were "in a dream." He stopped taking the medication after 2 days but continued to feel amotivated with decreased appetite and insomnia. Several days later, he developed ego-dystonic auditory hallucinations. He returned to the United States; was admitted to an inpatient psychiatric unit for 4 days; and given olanzapine 5 mg at bedtime, lorazepam 1 mg every evening, and melatonin 6 mg every evening. He experienced gradual improvement in symptoms and was discharged with olanzapine 5 mg daily and outpatient follow-up.

Discussion: Vertigoheel is a homeopathic preparation containing ambra grisea, Cocculus indicus, Conium maculatum, and petroleum. Psychosis was not reported in any of the randomized controlled trials evaluating the use of Vertigoheel for treatment of vertigo. A literature search revealed no published reports of psychosis as a result of administration of any components of Vertigoheel.

Conclusion: A possible causal relationship was observed between the homeopathic supplement Vertigoheel and an acute episode of psychosis in a young male patient with no comorbidities.

眩晕症致精神病1例报告。
目的:报告一例服用眩晕跟治疗头晕后出现精神病的病例。病例总结:28岁男性,无精神病史,出现5天抑郁和精神病加重。他否认目前使用处方药、酒精或非法药物。大约两周前,在德国探亲时,他出现头晕。德国的一位医生给他开了眩晕跟,每小时服一片,直到症状好转。这并没有改善他的头晕,但确实让他觉得自己好像“在做梦”。2天后停药,但仍有食欲下降和失眠的感觉。几天后,他出现了自我张力障碍幻听。他回到了美国;在精神科住院4天;睡前给予奥氮平5毫克,每晚给予劳拉西泮1毫克,每晚给予褪黑素6毫克。患者症状逐渐改善,出院时使用奥氮平5mg /天,门诊随访。讨论:眩晕足是一种顺势疗法制剂,含有黑斑草、凤眼草、锥体草和石油。在任何评估使用Vertigoheel治疗眩晕的随机对照试验中均未报告精神病。文献检索显示,没有发表的报告精神病作为眩晕足的任何成分的管理的结果。结论:顺势疗法补充剂Vertigoheel与一名无合并症的年轻男性患者急性精神病发作之间可能存在因果关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信